GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (FRA:K27) » Definitions » Net Income From Continuing Operations

Kodiak Sciences (FRA:K27) Net Income From Continuing Operations : €-241.56 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Kodiak Sciences Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Kodiak Sciences's net income from continuing operations for the three months ended in Dec. 2023 was €-54.58 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was €-241.56 Mil.

Kodiak Sciences Net Income From Continuing Operations Historical Data

The historical data trend for Kodiak Sciences's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences Net Income From Continuing Operations Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial -42.63 -109.41 -236.29 -315.13 -238.87

Kodiak Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.50 -66.11 -74.01 -46.86 -54.58

Kodiak Sciences Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-241.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kodiak Sciences (FRA:K27) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (FRA:K27) » Definitions » Net Income From Continuing Operations
Comparable Companies
CCCC CTMX ACXP VTGN ANVS ORMP CLDI CSBR STTK OMER OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KOD:USA K27:Germany
Address
1200 Page Mill Road, Palo Alto, CA, USA, 94304
Website
https://www.kodiak.com
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Kodiak Sciences (FRA:K27) Headlines

No Headlines